BioCryst price target raised to $27 from $17 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on BioCryst (BCRX) to $27 from $17 and keeps an Outperform rating on the shares. BioCryst is buying Astria Therapeutics (ATXS) to “supercharge” its earnings growth with long- acting HAE candidate navenibart, the analyst tells investors in a research note. The firm expects 3 month and 6 month navenibart doses to hit in Astria’s ongoing Phase 3 trial in early 2027 and believe its differentiated, long-acting convenience, coupled with impressive efficacy, will drive broad adoption right as BioCryst’s Orladeyo hits its peak penetration.